Newer Oral Antidepressants with Novel Receptor Mechanisms

Module 5 — Chapter 17: Antidepressant Drugs

Five Agents — Mechanism, Primary Use, and Key Caution
Agent Mechanism Primary Clinical Use Key Caution
Vortioxetine Serotonin transporter inhibition + serotonin-1A agonism + serotonin-3/7 antagonism (multimodal) Depression with prominent cognitive dysfunction; prior sexual dysfunction on selective serotonin reuptake inhibitor Nausea (dose-dependent); cytochrome P450 2D6 substrate — reduce dose with potent inhibitors (bupropion, fluoxetine)
Vilazodone Serotonin transporter inhibition + serotonin-1A partial agonism Depression with comorbid anxiety; patients seeking favorable sexual dysfunction profile Must take with food (bioavailability drops ~one-third fasted); prominent gastrointestinal adverse effects; titrate slowly
Trazodone Serotonin transporter inhibition + serotonin-2A antagonism + H1 and alpha-1 blockade Low-dose adjunct hypnotic (50–150 mg) for insomnia; rarely used as primary antidepressant Priapism in males (emergency — can cause permanent erectile dysfunction); orthostatic hypotension
Nefazodone Serotonin transporter inhibition + serotonin-2A antagonism (similar to trazodone) Refractory depression only — after all safer alternatives exhausted Black-box hepatotoxicity warning; branded product withdrawn 2004; potent cytochrome P450 3A4 inhibitor
Agomelatine Melatonin MT1 and MT2 receptor agonism + serotonin-2C antagonism; no monoamine transporter activity Depression with circadian disruption; no Food and Drug Administration approval — European and Australian use only Hepatotoxicity — liver function monitoring required; contraindicated with fluvoxamine and ciprofloxacin (cytochrome P450 1A2 inhibitors)
Clinical Niche and Adverse Effect Distinctions
Vortioxetine
Cognitive Benefit
  • Pro-cognitive effects beyond mood improvement
  • Favorable sexual dysfunction profile
  • No significant weight gain or QTc effect
  • Nausea is main adverse effect — start low
Trazodone
Hypnotic Role
  • Low dose (50–150 mg bedtime): hypnotic use
  • High dose (300–600 mg): antidepressant effect
  • No dependence, no scheduling
  • Priapism: warn male patients before first dose
Agomelatine
Circadian Niche
  • No sexual dysfunction
  • No discontinuation syndrome
  • Improves sleep architecture without sedation
  • Liver function monitoring required
  • Not available in United States
High-Yield Distinction — Nefazodone vs. Trazodone

Both are serotonin antagonist and reuptake inhibitors. Trazodone: commonly used as hypnotic, generally safe, priapism is main serious risk. Nefazodone: black-box hepatotoxicity, potent cytochrome P450 3A4 inhibitor, branded product withdrawn from United States market in 2004, now rarely prescribed. Same mechanism class — vastly different safety profiles.